December 11, 2007

ThromboGenics presents results of Phase I Trial of TB-402 at ASH... more »

ASH presentation »

December 4, 2007

ThromboGenics presents results of vitreomacular traction trial at ASRS... more »

Nov 14, 2007

ThromboGenics begins preclinical development of Anti-VPAC antibody for thrombocytopenia... more »

link to Blood publication »

Nov 2, 2007

ThromboGenics and BioInvent announce publication of exciting data on a novel class of angiogenesis inhibitors in Cell... more »

anti-PlGF mechanism of action »

Oct 4, 2007

ThromboGenics and Rhein Minapharm announce agreement for next-generation thrombolytic agent... more »

Sep 21, 2007

ThromboGenics completes enrolment of patients for the vitreomacular traction trial... more »

Sep 20, 2007

ThromboGenics announces exercise of 1.147.825 warrants... more »

Sep 7, 2007

ThromboGenics and BioInvent announce successful completion of phase I trial with TB-402... more »

Sep 4, 2007

ThromboGenics announces successful completion of tech transfer to Bharat Biotech... more »

Aug 24, 2007

ThromboGenics announces interim results... more »

July 5, 2007

ThromboGenics completes absorbtion of its subsidiary Thromb-X NV... more »

May 23, 2007

ThromboGenics plans to absorb its subsidiary Thromb-X NV... more »

Merger proposal

May 9, 2007

ThromboGenics succesfully completes private offering raising 23.9 million euro... more »

May 9, 2007

ThromboGenics engaged in private offering... more »

May 2, 2007

ThromboGenics announces progress on pre-clinical and clinical programs... more »

April 16, 2007

ThromboGenics announces license agreement with Millipore for commercialization of stem cell medium technology... more »

March 27, 2007

GO Capital becomes major shareholder in ThromboGenics... more »

March 2, 2007

Prof. Désiré Collen, Chairman and CEO of ThromboGenics, awarded 2007 Harvard Leadership Prize... more »

February 15, 2007

ThromboGenics announces business update and Half Year Results... more »

February 12, 2007

ThromboGenics and BioInvent receive approval to begin clinical trials for anticoagulant TB-402... more »

February 5, 2007

ThromboGenics strengthens management team with COO and Patent Counsel... more »

January 15, 2007

ThromboGenics and Geymonat awarded Euro 2 Million EU Grant for VASOPLUS Pro-Angiogenesis Programme... more »

January 8, 2007

ThromboGenics initiates Phase IIb U.S. clinical trial of Microplasmin in vitrectomy... more »

.

December 28, 2006

ThromboGenics and BioInvent awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme... more »

December 6, 2006

ThromboGenics announces license agreement with Bharat Biotech (India) for novel thrombolytic agent... more »

November 13, 2006

ThromboGenics announces IND clearance from FDA for microplasmin intraocular injection... more »

October 20 , 2006

ThromboGenics announces the first presentation of the results of the MIVI-I Phase IIa trial... more »

October 19 , 2006

Roche Diagnostics, ThromboGenics and Geymonat announced the signing of a license agreement... more »

September 26, 2006

ThromboGenics announces an update of its development plans for microplasmin in the field of peripheral occlusive disease... more »

September 22, 2006

ThromboGenics announces the initiation of a Phase IIa clinical trial to evaluate microplasmin for the intra-arterial treatment of stroke... more »

September 13, 2006

ThromboGenics announces that it has completed the enrolment and treatment of all 60 patients to be included in its MIVI-I trial... more »

August 30, 2006

ThromboGenics announces its Financial Calendar for 2006/2007... more »

August 16, 2006

ThromboGenics Appoints Chris Buyse as New Chief Financial Officer and Director... more »

July 31, 2006

ThromboGenics announces that the Over-Allotment Option has been fully exercised at the offer price, in accordance with its prospectus... more »

July 6, 2006

ThromboGenics raises the envisaged €35 million in its IPO and additionally €3.5 million in over-allotment shares will be allocated... more »

.

January 18, 2005

ThromboGenics Announces The Initiation of Phase II Trial of Microplasmin... more »

.

December 17, 2004

ThromboGenics and BioInvent Add New Anti-Angiogenesis Program to Collaboration... more »

September 27, 2004

ThromboGenics and BioInvent Strike Alliance to Jointly Develop Antibody-Based Therapeutics... more »

April 1, 2004

ThromboGenics Granted FDA Orphan Drug Designation for Microplasmin Use in Pediatric Eye Surgery... more »

March 10, 2004

ThromboGenics and NuVue Technologies to Collaborate on Development of Plasmin-Based Drugs for Visual Disorders... more »

February 25, 2004

ThromboGenics and Geymonat Announce Collaboration for Development of PlGF (Placental Growth Factor) in Angiogenesis... more »

.

July 10, 2003

New Study In July 1, 2003 Nature Medicine Highlights Role Of PlGF (Placental Growth Factor) in Angiogenesis... more »

October 15, 2003

ThromboGenics Reports New Embryonic Stem Cell Medium for Derivation of Non-Permissive Strains... more »